Personal profile
Biography
|
I am Personal Chair of Translational Liver Research and Honorary Consultant Hepatologist at the University of Edinburgh, UK. I have >30 years of hepatology research experience that spans basic science to clinical trials, giving me a multifaceted view of chronic liver disease. I am currently based in the new £92.5 million Institute for Regeneration and Repair (IRR) - the largest institute for regeneration and repair globally, hosting >600 scientists to facilitate the translation of discovery to therapy - and lead the ‘Translational Medicine’ theme in the Centre for Inflammation Research. I have a successful track record in translating scientific advances from bench to bedside and collaborating with Industry, running commercial and academic-sponsored observational studies (e.g., imaging/ biomarkers, large patient cohorts), interventional trials (e.g., recombinant relaxin, autologous macrophage cell therapy), discovery science, and mechanistic studies (e.g., preclinical evaluation of drug candidates). |
My clinical activity includes general hepatology clinics and management of hepatocellular carcinoma patients. I hold numerous advisory board/ clinical trial endpoint adjudication roles and am a National Institute for Health and Care Excellence (NICE) Medical Technologies Evaluation Programme (MTEP) advisor and Adoption & Implementation advisor. As an enthusiastic clinical educator, I contribute to undergraduate and postgraduate teaching at the University of Edinburgh. Patient and Public Involvement and Engagement is a high priority theme and, working closely with the British Liver Trust, helps to shape my research portfolio.
Education/Academic qualification
Doctor of Philosophy (PhD), University of Southampton
Award Date: 1 Jan 2007
Bachelor of Medicine, University of Southampton
Award Date: 1 Jan 1997
Bachelor of Science, University of Southampton
Award Date: 1 Jan 1996
Keywords
- RM Therapeutics. Pharmacology
- Liver fibrosis
- Portal hypertension
- Cirrhosis
- Hepatorenal syndrome
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Opportunities and challenges of artificial intelligence in hepatology
Morel, S. M. G., Wu, S., Kendall, T. J., Guha, I. N. & Fallowfield, J. A., 31 Jan 2026, In: NPJ Gut and liver. 3, 3.Research output: Contribution to journal › Review article › peer-review
Open AccessFile -
Breathomics: a non-invasive approach for the diagnosis of liver disease
Sinha, R. & Fallowfield, J. A., Dec 2025, In: Expert Review of Molecular Diagnostics. 25, 12, p. 837-839Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Disease-associated hepatocytes are predictive of outcomes and survival in MASLD beyond fibrosis staging
Carlessi, R., Kendall, T. J., Olynyk, J. K., Dwyer, B. J., Wallace, M. C., Fallowfield, J. A. & Tirnitz-Parker, J. E. E., 10 Sept 2025, In: Gut.Research output: Contribution to journal › Letter › peer-review
Open AccessFile -
Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration
Van Dijck, E., Van Laere, S., Logie, E., Timmermans, S., Fransen, E., Ibrahim, J., Kendall, T. J., Fallowfield, J. A., Mateiu, L. M., Libert, C., Van Camp, G., Verrijken, A., Van Gaal, L., Francque, S., Van Hul, W. & Berghe, W. V., 4 Aug 2025, In: Clinical Epigenetics. 17, 1, 138.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof-of-Concept Study
Sinha, R., Gillespie, S.-L., Brinkman, P., Bassett, P., Lockman, K. A., Jaap, A. J., Fallowfield, J. A., Hayes, P. C. & Plevris, J., 20 May 2025, In: Alimentary Pharmacology and Therapeutics.Research output: Contribution to journal › Article › peer-review
Open AccessFile
-
SteatoSITE
Kendall, T. (Principal Investigator) & Fallowfield, J. (Co-investigator)
8/04/24 → 7/04/26
Project: Research
-
GPR35: mechanisms of action and agonism as a potential therapeutic strategy for non-alcoholic fatty liver diseases
Fallowfield, J. (Principal Investigator)
2/03/24 → 1/03/27
Project: Research
-
Halt-RONIN: Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies
Bagnaninchi, P. (Co-investigator), Fallowfield, J. (Co-investigator) & Morton, N. (Co-investigator)
1/12/22 → 30/11/26
Project: Research
-
Halt-RONIN: Halt-RONIN: Discovering Chronic Inflammation Biomarkers That Define Key Stages In The Healthy-to-NASH (non-alcoholic Steatohepatitis) Transition To Inform Early Prevention And Treatment Strategies
Nelson, L. (Principal Investigator), Fallowfield, J. (Co-investigator), Bagnaninchi, P. (Co-investigator) & Morton, N. (Co-investigator)
1/12/22 → 30/11/26
Project: Research
-
Centre for Precision Medicine For The Liverapy
Forbes, S. (Principal Investigator), Dear, J. (Co-investigator), Dhaliwal, K. (Co-investigator), Fallowfield, J. (Co-investigator) & Forbes, S. (Co-investigator)
1/06/22 → 31/05/27
Project: Research
Press/Media
-
Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025
7/10/25
1 Media contribution
Press/Media: Research
-
Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025
7/10/25
1 Media contribution
Press/Media: Research
-
Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
3/09/25
1 Media contribution
Press/Media: Research
-
Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
3/09/25
1 Media contribution
Press/Media: Research
-
First patient dosed in Scotland with new liver disease treatment
2/09/25
1 Media contribution
Press/Media: Research